Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: J Thorac Oncol. 2019 Jun 19;14(10):1784–1793. doi: 10.1016/j.jtho.2019.06.002

Figure 2.

Figure 2.

Genomic landscape of lung cancer with concurrent EGFR/RB1/TP53 mutations. The type of genetic alteration (missense, in-frame, truncating, amplification, deep (homozygous) deletion, fusion/intragenic alteration) is described in the legend. The frequency of mutations is noted on the right. Mutations present in at least 5% of cases were included in the figure, as well as PIK3CA, MYC, and CREBBP mutations given their known relevance in small cell lung cancer.